ERBB2 and neoplasm: Moreover, PD-L1 expression could be decreased in a time/dose-dependent manner by treatment with HER2-targeting agents (lapatinib) [73], which supports the postulated dynamic crosstalk between TIME and tumour cells, especially those of the HER2-positive phenotype.